Beaumont Dialysis Svcs - Franklin Center is a medicare approved dialysis facility center in Southfield, Michigan and it has 18 dialysis stations. It is located in Oakland county at 26400 W 12 Mile Rd Ste 112, Southfield, MI, 48034. You can reach out to the office of Beaumont Dialysis Svcs - Franklin Center at (248) 228-8777. This dialysis clinic is managed and/or owned by Beaumont Hospital. Beaumont Dialysis Svcs - Franklin Center has the following ownership type - Non-Profit. It was first certified by medicare in October, 2010. The medicare id for this facility is 232666 and it accepts patients under medicare ESRD program.
| Name | Beaumont Dialysis Svcs - Franklin Center |
|---|---|
| Location | 26400 W 12 Mile Rd Ste 112, Southfield, Michigan |
| No. of Dialysis Stations | 18 |
| Medicare ID | 232666 |
| Managed By | Beaumont Hospital |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 26400 W 12 Mile Rd Ste 112, Southfield, Michigan, 48034 | |
| (248) 228-8777 | |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| NPI Number | 1194211433 |
| Organization Name | Fresenius Kidney Care Beaumont Health - Franklin Center |
| Doing Business As | Fms Beaumont Health, Llc |
| Address | 26400 W 12 Mile Rd Ste 112 Southfield, Michigan, 48034 |
| Phone Number | (781) 699-9000 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| NPI Number | 1669703799 |
| Doing Business As | Beaumont Kidney Specialty Services Llc |
| Address | 26400 W 12 Mile Rd Southfield, Michigan, 48034 |
| Phone Number | (248) 457-7648 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| NPI Number | 1851886592 |
| Organization Name | Fresenius Kidney Care Franklin Center |
| Doing Business As | Fms Rochester Hills, Llc |
| Address | 26400 W 12 Mile Rd Ste 112 Southfield, Michigan, 48034 |
| Phone Number | (781) 699-9000 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 74% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 13% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 13% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 14% |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 22% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 18% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 45% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 12% |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 77% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 23% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 48% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 37% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 80 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 9 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 138 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1100 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Beaumont Dialysis Svcs - Franklin Center with elevated calcium levels.
| Patients with hypercalcemia | 138 |
| Hypercalcemia patient months | 1105 |
| Patients with Serumphosphor | 148 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 38 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 110 |
| Patient months included in arterial venous fistula and catheter summaries | 910 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 48 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 121 |
| Hospitalization Rate in facility | 296.9 (Worse than Expected) |
| Hospitalization Rate: Upper Confidence Limit | 431.7 |
| Hospitalization Rate: Lower Confidence Limit | 216.1 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Beaumont Dialysis Svcs - Franklin Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 30 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.6 |
| Readmission Rate: Lower Confidence Limit | 22.9 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Beaumont Dialysis Svcs - Franklin Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.59 (As Expected) |
| SIR: Upper Confidence Limit | 2.53 |
| SIR: Lower Confidence Limit | .94 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Beaumont Dialysis Svcs - Franklin Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 93 |
| Transfusion Rate in facility | 107.8 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 167.1 |
| Transfusion Rate: Lower Confidence Limit | 73.4 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Beaumont Dialysis Svcs - Franklin Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 503 |
| Mortality Rate in facility | 18.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 22.7 |
| Mortality Rate: Lower Confidence Limit | 14.2 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago
Cornerstone Dialysis Of Davita Location: 23857 Greenfield Rd, Southfield, Michigan, 48075 Phone: (248) 569-6111 |
Southfield West Dialysis Of Davita Location: 21900 Melrose Ave, Southfield, Michigan, 48075 Phone: (248) 356-8079 |
Nw Detroit Dialysis - Lahser Satellite Location: 25664 Lahser Road, Southfield, Michigan, 48034 Phone: (248) 358-7521 |
Davita - Riverwood Dialysis Location: 24465 W 10 Mile Rd, Southfield, Michigan, 48033 Phone: (248) 352-3137 |
News Archive
The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
Experts agree that, more than ever before, modern wars will be fought in the cyber zone, targeting an enemy's communications technology to cause untold damage. Now a Tel Aviv University researcher is suggesting that the same tactics should be employed in the battle against one of the body's deadliest enemies - cancer.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
› Verified 9 days ago